HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[A case of severe systemic juvenile idiopathic arthritis introduced tocilizumab in early phase of the disease].

Abstract
A 14-year-old boy was admitted in the former hospital with remittent fever, erythematous rash, joint pain, and muscle pain. Antibiotics were ineffectively administered and then, methylprednisolone (mPSL) pulse therapy with methotrexate was introduced under the diagnosis of suspected systemic juvenile idiopathic arthritis (JIA). However, he still had clinical symptoms and signs, and was transferred to our hospital. Re-examination revealed no malignancies including acute leukemia by bone marrow aspiration, no infectious agents by septic work, and no significant increases of antibodies against several viruses including CMV, EBV, HSV, Parvovirus B19, adenovirus, and so forth. FDG-PET demonstrated the accumulation of (18)F-FDG in bone marrows suggesting systemic JIA. Laboratory findings were leukocytosis and granulocytosis, elevated levels of C-reactive protein, D-dimer, ferritin, and interleukin-6. He was finally diagnosed as having severe systemic JIA. Thus, soon after the additional mPSL pulse therapy, tocilizumab (TCZ) was successfully introduced. In conclusion, for systemic JIA patients with severe systemic inflammation, it will be reasonable to introduce tocilizumab earlier than the guideline suggested to reduce side effects of long-term and large amounts of steroids and to protect the transition to macrophage activation syndrome. Further studies will be needed to recommend appropriate timing of tocilizumab introduction.
AuthorsTakeshi Ikegawa, Kazuko Yamazaki, Kenichi Nishimura, Taichi Kanetaka, Masako Kikuchi, Tomo Nozawa, Ryouki Hara, Tomomi Sato, Nodoka Sakurai, Shumpei Yokota
JournalNihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology (Nihon Rinsho Meneki Gakkai Kaishi) Vol. 37 Issue 3 Pg. 176-82 ( 2014) ISSN: 1349-7413 [Electronic] Japan
PMID24974931 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antibodies, Monoclonal, Humanized
  • IL6 protein, human
  • Interleukin-6
  • tocilizumab
Topics
  • Adolescent
  • Antibodies, Monoclonal, Humanized (therapeutic use)
  • Arthritis, Juvenile (diagnosis, drug therapy, immunology)
  • Biopsy
  • Early Intervention, Educational
  • Humans
  • Interleukin-6 (blood)
  • Male
  • Multimodal Imaging
  • Positron-Emission Tomography
  • Tomography, X-Ray Computed

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: